Welcome to our dedicated page for Pluri SEC filings (Ticker: PLUR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pluri Inc. SEC filings document the governance, capital-structure, listing-status, and material-event disclosures of a biotechnology company using a proprietary cell-based platform. Proxy materials cover annual shareholder meeting matters, director elections, auditor ratification, and board governance.
Pluri’s Form 8-K filings record events such as board composition changes, executive equity awards, Nasdaq Capital Market listing-standard notices and compliance updates, material agreements, shareholder voting matters, and capital-structure disclosures. These filings provide the formal record for corporate actions affecting the company’s common shares, governance framework, and public-company reporting obligations.
Pluri Inc. (PLUR) operates a 3D cell expansion platform applied across regenerative medicine, food-tech (Ever After Foods), AgTech and a CDMO business. The company reported continued operating losses (losses of $23,250 for year ended June 30, 2025) and negative operating cash flow of $18,211, and states it must secure additional liquidity to support commercialization and R&D. Pluri completed the Kokomodo acquisition (79% for 976,139 shares), recording $2,823 of identifiable intangible assets and $3,136 of goodwill. The company has an outstanding EIB loan (linked principal and accrued interest of $27,289 presented as short-term) and is in discussions to restructure its terms. Share financings and warrant/pre-funded-warrant issuances occurred in fiscal 2025, and shareholder approval was obtained for certain warrant classifications. The company regained compliance with Nasdaq listing standards.
Pluri Inc. (PLUR) operates a 3D cell expansion platform applied across regenerative medicine, food-tech (Ever After Foods), AgTech and a CDMO business. The company reported continued operating losses (losses of $23,250 for year ended June 30, 2025) and negative operating cash flow of $18,211, and states it must secure additional liquidity to support commercialization and R&D. Pluri completed the Kokomodo acquisition (79% for 976,139 shares), recording $2,823 of identifiable intangible assets and $3,136 of goodwill. The company has an outstanding EIB loan (linked principal and accrued interest of $27,289 presented as short-term) and is in discussions to restructure its terms. Share financings and warrant/pre-funded-warrant issuances occurred in fiscal 2025, and shareholder approval was obtained for certain warrant classifications. The company regained compliance with Nasdaq listing standards.
Pluri Inc. reported that its board of directors elected Mr. Eitan Ajchenbaum to serve as a director, effective September 10, 2025, filling a vacancy created after Doron Birger’s service ended following the June 30, 2025 annual meeting. He will serve until the next general meeting at which directors are elected or as provided in the company’s bylaws.
Mr. Ajchenbaum, age 63, is a Certified Public Accountant in Israel with more than 30 years of senior executive and board experience in public and private companies. He currently serves as Chief Financial Officer and Deputy Chief Executive Officer of WeSure Global Tech Ltd., and previously held long‑term senior roles at Berkshire Hathaway Guard and other Israeli public companies.
He will serve as a non‑executive director with the same rights and privileges as other non‑executive directors, including information access, expense reimbursement, and D&O insurance coverage. He has been appointed Chairman of the Audit Committee, designated as an audit committee financial expert, and named sole member of the Board’s Investment Committee. The company states there are no special arrangements, family relationships, or related‑party transactions connected to his appointment.